The Medical Advisor

Quick Answer:  The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Despite  trillions spent on cancer research  ( The Lancet Oncology ), cancer still  kills around 10 million people a year  ( WHO )...

Introduction In recent years, GLP-1 receptor agonists have emerged as one of the most important breakthroughs in modern metabolic medicine. Originally developed to treat type 2 diabetes, these medications are now widely used for weight loss, cardiovascular risk reduction, and metabolic disease management . Drugs such as Ozempic, Wegovy, and Mounjaro have rapidly gained global attention for their ability to produce significant and sustained weight loss while improving multiple cardiometabolic risk factors. GLP-1 (glucagon-like peptide-1) is a natural hormone released from the gut after eating. It plays a key role in regulating blood sugar, appetite, and digestion. By mimicking or enhancing this hormone’s activity, GLP-1 drugs help reduce hunger, slow gastric emptying, improve insulin secretion, and support healthier glucose control. Over the past decade, large randomized clinical trials have demonstrated that these medications can lead to 10–20% reductions in body weight , alongside me...

Introduction: From Population Medicine to N=1 Healthcare By 2026, medicine is undergoing a quiet but profound transformation. Instead of treating patients based primarily on population averages, healthcare is shifting toward personalized N=1 medicine — where prevention, diagnosis, and treatment are optimized for a single individual using real-time data. At the center of this shift are AI-powered wearables , capable of continuously monitoring physiology, behavior, and biochemistry, then using artificial intelligence to generate personalized health insights. Together, they are redefining how we understand disease risk, treatment response, and long-term health optimization. What Is Personalized N=1 Medicine? N=1 medicine refers to individualized healthcare strategies designed for one person, not a statistical cohort. Instead of asking: “What works for most patients?” N=1 medicine asks: “What works for this person — right now?” Core Principles of N=1 Medicine Continuous data collection...

Abstract Despite increasing interest in drug repurposing, most off-patent pharmaceuticals fail to progress to Phase III randomized controlled trials (RCTs), even when supported by plausible biological mechanisms and early clinical signals. This absence of late-stage evidence is often misinterpreted as lack of efficacy. In reality, it reflects structural, economic, and regulatory barriers inherent to modern evidence-generation systems. This commentary examines why off-patent drugs rarely reach Phase III trials and discusses emerging alternatives — including in-silico trials and N-of-1 trial designs — as complementary approaches for evaluating non-proprietary therapies. Keywords: Off-patent drugs, drug repurposing, Phase III trials, in-silico trials, N-of-1 trials, evidence-based medicine, regulatory science Scope and Intent of This Commentary This article is an analytical commentary , not a treatment recommendation. It does not advocate off-label prescribing or replacement of standar...

Within modern evidence-based medicine, case series and case reports are frequently dismissed as “anecdotal” and therefore regarded as scientifically weak. In oncology in particular, the prevailing paradigm holds that only large randomized controlled trials (RCTs) can establish the validity of a treatment. While such trials are essential for determining the efficacy and safety of a single intervention under controlled conditions, the history of medicine consistently demonstrates that discovery rarely begins with randomization—it begins with observation. Clinicians notice unexpected responses in individual patients; outcomes emerge that defy conventional expectations; and, over time, patterns begin to form. It is also important to recognize the structural limitations of the current research ecosystem. Large RCTs are often impractical for off-label or repurposed strategies, particularly those involving inexpensive agents, dietary interventions, or lifestyle modifications. These approache...